1
Home
Companies

Captor Therapeutics

Captor Therapeutics
Leadership team

Dr. Thomas Shepherd Ph.D. (CEO & Pres of the Management Board)

Mr. Sylvain Cottens (Co-Founder & Sr. VP of Chemistry)

Mr. Radoslaw Krawczyk (Member of the Management Board & Chief Financial Officer)

Products/ Services
Biopharma, Biotechnology, Medical
Number of Employees
100 - 500
Headquarters
Wroclaw, Dolnoslaskie, Poland
Established
2017
Revenue
500K - 2M
Traded as
WSE:CTX
Social Media
URL
https://www.captortherapeutics.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has five projects at the preclinical stage. The company was incorporated in 2015 and is based in Wroclaw, Poland.
History

Captor Therapeutics Inc. was founded in 2019 and is focused on developing small molecule therapies to treat various cancers. The company’s lead product is a dual inhibitor of PI3K and mTOR (originally developed by the National Cancer Institute) that is currently in a phase I clinical trial. Additionally, Captor Therapeutics is actively pursuing several other small molecule targets for their potential use in treating cancer.

Mission
Captor Therapeutics is committed to discovering, developing, and commercializing novel treatment options for cancer that will improve the quality of life for patients suffering from this disease.
Vision
To develop innovative small molecule therapies that target specific pathways and proteins to treat cancer, with the goal of realizing an improved quality of life and overall survival benefit among cancer patients.
Key Team

Mr. Michal Walczak (Member of Management Board & Chief Scientific Officer)

Recognition and Awards
Captor Therapeutics won the 2020 BioPharmaceutics Award for Innovation and Entrepreneurial Enterprise in 2021. Captor Therapeutics is also a recipient of the 2020 Celleration Award for Artificial Intelligence in Biology at MIT and the 2019 Latham Award for Therapeutic Development at Johns Hopkins.
References

https://in.investing.com/equities/captor-therapeutics

https://finance.yahoo.com/quote/CTX.WA/profile?p=CTX.WA

https://www.crunchbase.com/organization/captor-therapeutics-sa

https://www.captortherapeutics.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Captor Therapeutics
Leadership team

Dr. Thomas Shepherd Ph.D. (CEO & Pres of the Management Board)

Mr. Sylvain Cottens (Co-Founder & Sr. VP of Chemistry)

Mr. Radoslaw Krawczyk (Member of the Management Board & Chief Financial Officer)

Products/ Services
Biopharma, Biotechnology, Medical
Number of Employees
100 - 500
Headquarters
Wroclaw, Dolnoslaskie, Poland
Established
2017
Revenue
500K - 2M
Traded as
WSE:CTX
Social Media
URL
https://www.captortherapeutics.com